Dianthus Therapeutics Prices $625 Million Public Offering

Got story updates? Submit your updates here. ›

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company focused on developing therapies for severe autoimmune diseases, announced the pricing of a $625 million underwritten public offering. The company sold 7,313,582 shares of common stock at $81 per share, as well as pre-funded warrants to purchase up to 402,468 shares at $80.999 per warrant. Dianthus intends to use the net proceeds to advance its clinical and preclinical programs, commercial readiness activities, and for general corporate purposes.

Why it matters

This significant capital raise will provide Dianthus with the resources to accelerate the development of its pipeline of next-generation autoimmune disease treatments. As a clinical-stage biotech, securing this level of funding is crucial for the company to advance its therapies through late-stage trials and towards potential regulatory approvals and commercialization.

The details

The offering is expected to close on March 12, 2026, subject to customary closing conditions. Dianthus has also granted the underwriters a 30-day option to purchase up to an additional 1,157,407 shares. The joint book-running managers for the offering are Jefferies, TD Cowen, Evercore ISI, Stifel, Guggenheim Securities, and William Blair, with LifeSci Capital acting as Dianthus' financial advisor.

• The offering is expected to close on March 12, 2026.